METTL3 and cancer: The clinical relevance of this pathway is increasingly evident, as aberrant expression of m6A regulators such as METTL3, FTO, ALKBH5, or IGF2BPs correlates with poor prognosis, advanced disease stage, therapy resistance and immune evasion, in multiple cancer types [108,109,110,111].